radiation as an immunological adjuvant: current evidence on dose and fractionation

النقرات: 289
المعرّف: 237870
2012
PDF مجاني
مقاييس جودة وأداء المقال
الجودة الإجمالية
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
تقييم الجودة بالذكاء الاصطناعي
لم يتم التحليل
Readership in this journal
Popular

Ranked #124 of 207 articles by views in international journal of heat and technology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
الملخص
Ionizing radiation to a cancer site has the ability to convert the irradiated tumor in an immunogenic hub. However, radiation is a complex modifier of the tumor microenvironment and, by itself, is seldom sufficient to induce a therapeutically significant anti-tumor immune response, since it can also activate immune suppressive pathways. While several combinations of local radiation and immunotherapy have been shown in pre-clinical models to induce powerful anti-tumor immunity, the optimal strategy to achieve this effect remains to be defined. When used in vivo, radiation effects on tumors depend on the dose per fraction applied, the number of fractions used, and the total dose. Moreover, the interplay of these three variables is contingent upon the tumor setting studied, both in preclinical and clinical applications. To enable repair of the collateral damage to the normal tissue, radiation is usually given in multiple fractions, usually of 2 Gy. Generally, the use of larger fractions is limited to sterotactic applications, whereby optimal immobilization reduces inter and intra-fraction movement and permits a very conformal delivery of dose to the target, with optimal exclusion of normal tissue. Translation of the partnership of radiation and immunotherapy to the clinic requires a careful consideration of the radiation regimens used. To date, little is known on whether different dose/fractionation regimens have a specific impact on the anti-tumor immune response. Most experiments combining the two modalities were conducted with single fractions of radiotherapy. However, there is at least some evidence that when combined with some specific immunotherapy approaches, the ability of radiation to promote anti-tumor immunity is dependent on the dose and fractionation employed. We critically review the available in vitro and in vivo data on this subject and discuss the potential impact of fractionation on the ability of radiation to synergize with immunotherapy.
المفتاح المرجعي
edemaria2012frontiersradiation استخدم هذا المفتاح للاستشهاد التلقائي في المخطوطة أثناء استخدام مدير المخطوطات أو مدير الأطروحات من SciMatic
المؤلفون ;Sandra eDemaria;Silvia C Formenti
مجلة international journal of heat and technology
السنة 2012
DOI
10.3389/fonc.2012.00153
URL
http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00153/full
الكلمات المفتاحية
inflammation t cells immunotherapy dendritic cells fractionation Oncology including cancer and carcinogens tumors abscopal effectneoplasms

الاستشهادات

لم يتم العثور على استشهادات. لإضافة استشهاد، تواصل مع المشرف على info@scimatic.org

التعليقات

لا توجد تعليقات بعد. كن أول من يعلق على هذا المقال.